A chenodeoxycholic derivative, HS-1200, induces apoptosis and cell cycle modulation via Egr-1 gene expression control on human hepatoma cells

Cancer Letters

Volumn 270, Issue 1, 2008, Pages 77-86

  Park, Sang Eun ^a   Lee, Sun Wha ^a   Hossain, Mohammad Akbar ^a   Kim, Min Young ^a   Kim, Mi Na ^a   Ahn, Eun Young ^a   Park, Young Chul ^b   Suh, Hongsuk ^a   Kim, Gi Young ^c   Choi, Yung Hyun ^d   Kim, Nam Deuk ^a  

^a Pusan National University   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Jeju National University   (South Korea)

^d Dong Eui University   (South Korea)

Author keywords

Apoptosis; Cell cycle; Chenodeoxycholic acid derivative; Cyclooxygenase 2; Egr 1; HS 1200

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CHENODEOXYCHOLIC ACID DERIVATIVE; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLOOXYGENASE 2; EARLY GROWTH RESPONSE FACTOR 1; HS 1200; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL LINE; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG MECHANISM; EGR1 GENE; FLOW CYTOMETRY; GENE; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; GROWTH INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; NUCLEAR STAINING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; CHENODEOXYCHOLIC ACID; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLOOXYGENASE 2; EARLY GROWTH RESPONSE PROTEIN 1; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 50649114194     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.04.038     Document Type: Article

References (54)

1. McGlynn K.A., and London W.T. Epidemiology and natural history of hepatocellular carcinoma. Best Prac. Res. Clin. Gastroenterol. 19 (2005) 3-23
2. Martinez J.D., Stratagoules E.D., LaRue J.M., Powell A.A., Gause P.R., Craven M.T., Payne C.M., Powell M.B., Gerner E.W., and Earnest D.L. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr. Cancer 31 (1998) 11-118
3. Hofmann A.F. Chemistry and enterohepatic circulation of bile acids. Hepatology 4 suppl (1984) 4S-14S
4. Martinez-Diez M.C., Serrano M.A., Monte M.J., and Marin J.J. Comparison of the effects of bile acids on cell viability and DNA synthesis by rat hepatocytes in primary culture. Biochim. Biophys. Acta 1500 (2000) 153-160
5. Patel T., Bronk S.F., and Gores G.J. Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes. J. Clin. Invest. 94 (1994) 2183-2192
6. Rust C., Karnitz L.M., Paya C.V., Moscat J., Simari R.D., and Gores G.J. The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J. Biol. Chem. 275 (2000) 20210-20216
7. Patel T., Roberts L.R., Jones B.A., and Gores G.J. Dysregulation of apoptosis as a mechanism of liver disease: an overview. Semin. Liver Dis. 18 (1998) 105-114
8. Powell A.A., LaRue J.M., Batta A.K., and Martinez J.D. Bile acid hydrophobicity is correlated with induction of apoptosis and/or growth arrest in HCT116 cells. Biochem. J. 356 (2001) 481-486
9. Kim N.D., Im E., Choi Y.H., and Yoo Y.H. Modulation of the cell cycle and induction of apoptosis in human cancer cells by synthetic bile acids. Curr. Cancer Drugs Targets 6 (2006) 681-689
10. Baek J.H., Kim J., Kang C., Lee Y.S., and Kim K.W. Induction of apoptosis by bile acids in HepG2 human hepatocellular carcinoma cells. Korean J. Physiol. Pharmacol. 1 (1997) 107-115
11. Park Y.H., Kim J., Baek J., Jung E., Kim T., Suh H., Park M.H., and Kim K.W. Induction of apoptosis in HepG2 human hepatocellular carcinoma cells by a novel derivative of ursodeoxycholic acid (UDCA). Arch. Pharm. Res. 20 (1997) 29-33
12. Im E.O., Lee S., Suh H., Kim K.W., Bae Y.T., and Kim N.D. A novel ursodeoxycholic acid derivative induces apoptosis in human MCF-7 breast cancer cells. Pharm. Pharmacol. Commun. 5 (1999) 293-298
13. Im E.O., Choi Y.H., Paik K.J., Suh H., Jin Y., Kim K.W., Yoo Y.H., and Kim N.D. Novel bile acid derivatives induce apoptosis via a p5 3-independent pathway in human breast carcinoma cells. Cancer Lett. 163 (2001) 83-93
14. Choi Y.H., Im E.O., Suh H., Jin Y., Lee W.H., Yoo Y.H., Kim K.W., and Kim N.D. Apoptotic activity of novel bile acid derivatives in human leukemic T cells through the activation of caspases. Int. J. Oncol. 18 (2001) 979-984
15. Choi Y.H., Im E.O., Suh H., Jin Y., Yoo Y.H., and Kim N.D. Apoptosis and modulation of cell cycle control by synthetic derivatives of ursodeoxycholic acid and chenodeoxycholic acid in human prostate cancer cells. Cancer Lett. 199 (2003) 157-167
16. Park S.E., Choi H.J., Yee S.B., Y Chung H., Suh H., Choi Y.H., Yoo Y.H., and Kim N.D. Synthetic bile acid derivatives inhibit cell proliferation and induce apoptosis in HT-29 human colon cancer cells. Int. J. Oncol. 25 (2004) 231-236
17. Jeong J.H., Park J.S., Moon B., Kim M.C., Kim J.K., Lee S., Suh H., Kim N.D., Kim J.M., Park Y.C., and Yoo Y.H. Orphan nuclear receptor Nur77 translocates to mitochondria in the early phase of apoptosis induced by synthetic chenodeoxycholic acid derivatives in human stomach cancer cell line SNU-1. Ann. N.Y Acad. Sci. 1010 (2003) 171-177
18. Yee S.B., Yeo W.J., Park B.S., Kim J.Y., Baek S.J., Kim Y.C., Seo S.Y., Lee S.H., Kim J.H., Suh H., Kim N.D., Lim Y.J., and Yoo Y.H. Synthetic chenodeoxycholic acid derivatives inhibit brain tumor growth in vitro and in vivo. Int. J. Oncol. 27 (2005) 653-659
19. Chinnaiyan A.M., and Dixit V.M. The cell-death machine. Curr. Biol. 6 (1996) 555-562
20. Kasibhatla S., and Tseng B. Why target apoptosis in cancer treatment?. Mol. Cancer Ther. 2 (2003) 573-580
21. Lemaire P., Revelant O., Bravo R., and Charnay P. Two mouse genes encoding potential transcription factors with identical DNA-binding domains are activated by growth factors in cultured cells. Proc. Natl. Acad. Sci. USA 85 (1998) 4691-4695
22. Milbrandt J. A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor. Science 238 (1987) 797-799
23. Angel P., and Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta 1072 (1991) 129-557
24. Beckmann A.M., and Wilce P.A. Egr transcription factors in the nervous system. Neurochem. Int. 31 (1997) 477-516
25. Herdegen T., and Leah J.D. Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Res. Brain Res. Rev. 28 (1998) 370-490
26. Liu C., Rangnekar V., Adamson E., and Mercola D. Suppression of growth and transformation and induction of apoptosis by EGR-1. Cancer Gene Ther. 5 (1998) 3-28
27. Cao X.M., Guy R., Sukhatme V., and Tan Y. Regulation of the Egr-1 gene by tumor necrosis factor and interferons in primary human fibroblasts. J. Biol. Chem. 267 (1992) 1345-1349
28. Hodge C., Liao J., Stofega M., Guan K., Carter-Su C., and Schwartz J. Growth hormone stimulates phosphorylation and activation of elk-1 and expression of c-fos, egr-1, and junB through activation of extracellular signal-regulated kinases1 and 2. J. Biol. Chem. 273 (1998) 31327-31336
29. Morawietz H., Ma Y., Vives F., Wilson E., Sukhatme V., Holtz J., and Ives H. Rapid induction and translocation of Egr-1 in response to mechanical strain in vascular smooth muscle cells. Circ. Res. 84 (1999) 678-687
30. Yan S.F., Fujita T., Lu J., Okada K., Shan Zou Y., Mackman N., Pinsky D.J., and Stern D.M. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat. Med. 6 (2000) 1355-1361
31. Datta R., Rubin E., Sukhatme V., Qureshi S., Hallahan D., R Weichselbaum R., and Kufe D.W. Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc. Natl. Acad. Sci. USA 89 (1992) 10149-10153
32. Kaina B., Haas S., and Kappes H. A general role for c-Fos in cellular protection against DNA-damaging carcinogens and cytostatic drugs. Cancer Res. 57 (1997) 2721-2731
33. Choi H.J., Yee S.B., Park S.E., Im E., Jung J.H., Chung H.Y., Choi Y.H., and Kim N.D. Petrotetrayndiol A induces cell cycle arrest and apoptosis in SK-MEL-2 human melanoma cells through cytochrome c-mediated activation of caspases. Cancer Lett. 232 (2006) 214-225
34. Wang D., and Dubois R.N. Cyclooxygenase-2: a potential target in breast cancer. Semin. Oncol. 31 (2004) 64-73
35. DuBois R.N., and Smalley W.E. Cyclooxygenase, NSAIDs, and colorectal cancer. J. Gastroenterol. 31 (1996) 898-906
36. Liu C.H., Chang S.H., Narko K., Trifan O.C., Wu M.T., Smith E., Haudenschild C., Lane T.F., and Hla T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis intransgenic mice. J. Biol. Chem. 276 (2001) 18563-18569
37. Gately S., and Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog. Exp. Tumor Res. 37 (2003) 179-192
38. Cao Y., and Prescott S.M. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J. Cell Physiol. 190 (2002) 279-286
39. Ahmed M.M. Regulation of radiation-induced apoptosis by early growth response-1 gene in solid tumors. Curr. Cancer Drug Targets 4 (2004) 43-52
40. Luan Y., and Xu W. The function of the selective inhibitors of cyclooxygenase 2. Mini. Rev. Med. Chem. 12 (2006) 1375-1381
41. Harris R.E., Beebe-Donk J., and Alshafie G.A. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies. Subcell Biochem. 42 (2007) 193-212
42. Gerald T., and Giuseppe C. Regulation of life and death by the zinc finger transcription factor Egr-1. J. Cell Physiol. 193 (2002) 287-292
43. Ponchel F F., and Milner J. Temperature sensitivity of human wild-type and mutant p53 proteins expressed in vivo. Br. J. Cancer 77 (1998) 1555-1561
44. Salomons G.S., Brady H.J., Verwijs-Janssen M., van den Berg J.D., Hart A.A., van den Berg H., Behrendt H., Hahlen K., and Smets L.A. The Bax alpha: Bcl-2 ratio modulates the response to dexamethasone in leukaemic cells and is highly variable in childhood acute leukaemia. Int. J. Cancer 71 (1997) 959-965
45. Koff A., Giordano A., Desai D., Yamashita K., Harper J.W., Elledge S., Nishimoto T., Morgan D.O., Franza B.R., and Roberts J.M. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science 257 (1992) 1689-1694
46. Harper J.W., and Elledge S.J. Cdk inhibitors in development and cancer. Curr. Opin. Genet. Dev. 6 (1996) 56-64
47. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., and Vogelstain B. WAF1, a potential mediator of p53 suppression. Cell 75 (1993) 817-825
48. WAF1/CIP1 expression by p53-independent pathways. Cancer Res. 54 (1994) 3391-3395
49. Han Q.X., Ordonez J.V., Shroot B., and Fontana J.A. p53-independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 11 (1995) 493-504
50. Gartenhaus R.B., Wang P., and Hoffmann P. Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with adriamycin by using a p53-independent pathway. Proc. Natl. Acad. Sci. USA 93 (1996) 265-268
51. Williams C.S., Mann M., and DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18 (1999) 7908-7915
52. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., and DuBois R.N. Up regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994) 1183-1188
53. Fujita H., Koshida K., and Keller E.T. Cyclooxygenase-2 promotes prostate cancer progression. The Prostate 53 (2002) 232-240
54. Meric J.B., Rottey S., Olaussen K., Soria J.C., Khayat D., Rixe O., and P Spano J. Cyclooxygenase-2 as a target for anticancer drug development. Crit. Rev. Oncol. Hematol. 59 (2006) 51-64